Cerebrolysin 5×10 Ml


original Cerebrolysin from Ever pharma

box of 5×10 milliliter

Unique peptidergic nootropic for the modern, safe and effective treatment of disturbed cerebral functions, metabolic disturbances

Cerebrolysin® could be a peptide preparation extracted from porcine brain. the solution is ready for injection or infusion, free of proteins, lipids and antigenic properties.

Cerebrolysin could be a peptide mixture obtained by standardized enzymatic (proteo)lysis breakdown of pure porcine brain proteins. It consists of approximately twenty fifth biologically active low molecular weight peptides and amino acids that are ready to penetrate the blood–brain barrier in significant amounts and mimic the consequences of NGF. one milliliter of injectable solution contains 215,2 mg of protein lysate and excipients (sodium hydroxide, water).

Route of administration

Solution for intramuscular and intravenous injection or intravenous infusion.


The efficacy of Cerebrolysin® is proved in various animal experiments and clinical trials. Cerebrolysin® could be a brain-specific peptidergic nootropic drug ready to have an effect on the central nervous system in a multimodal method.
In Controlled clinical trials Cerebrolysin® treatment results in an improvement within the cognitive performance and mood of patients affected by Alzheimer’s illness. Therefore, the amount of care required by these sufferers decreases.
In these patients 61.7% of the Cerebrolysin® – treated group (as assessed by the Clinical global Impressions scale CGI ). Another clinical test in patients with vascular dementia demonstrates improvement of memory performance within the group receiving Cerebrolysin® treatment. an improvement within the world clinical image is additionally detected during this sickness. a further study involving patients from
nine totally different illness entities established the effectiveness of Cerebrolysin® through the utilization of eleven psychological tests subjected to a variance analysis.

After the stroke and craniocerebral truma treatment wit Cerebrolysin® leads to an accelerated recovery.
Literature on Cerebrolysin® is available upon request.


Cerebrolysin® passes through the blood-brain barrier . Up to eight hours when iv administration of Cerebrolysin® neurotophic activity may be detected within the human long-lasting effects even when one iv administarion.

Toxicological properties

Cerebrolysin® is usually well tolerated and possesses an especially high margin of safety. In human therapeutic dosages this produces virtually no poisonous symptoms. The toxicologic information are listed below.
Chronic toxicity (multiple doses over six months) rats received up to 12.5ml/kg weight daily for twenty six weeks. only moderate changes within the blood count were observed, dogs ; the best administrated doses were 9ml/kg weight daily for twenty eight days (about ten times the human therapeutic dosage) and 4.5ml/kg weight daily for twenty six weeks (about 5 times the human therapeutic dosage): no general substance-dependent intolerance reactions were determined .
Reproductive toxicity: It was injected iv to the dams at the best possible volumes: in no case was an alteration of the gestagenic period determined, in rabbits. Neither embryotoxic nor teratogenic effects nor
impairments of embryonic or neonatal developments were found; no influence on the issue (F1 and F2 generations) was evident. Influence on the fertility and reproductive performance of the parent anilmals potential, result or carcinogenicity in toxicologic tests, neither in vitro nor in vivo.


• disturbances of concentration and memory
• degenerative dementias, together with Alzheimer’s illness
• vascular demenatias, eg multi-infarct dementia
• mixed types of dementia (degenerative and tube contribution)
• sequels of stroke (ischaemic and haemorrhagic)
• posttraumatic or postoperative complaints, eg following cerebral
contusion, concussion, or neurosurgical operation.


• hypersensitivity to at least one of the elements of the drug
• status epilepticus or grand mal conulsions; a rise within the seizure
frequency is also seen in these cases
• status epilepticus or grand mal conulsions; a rise within the seizure
frequency is also seen in these cases
• severe impairments of renal function

Side effects

Cerebrolysin® is usually well tolerated. If injected too quick it should cause a moderate heat sensation. In very rare cases a hypersensitivity manifested itself as chills, headaches or as slight increase in body
temperature the reason for that is probably the hyperresponiveness of the patient. In no case so far has the undesirable result persisted or proven threatening to the patient.

Warning and precautional measures

Patients with severe renal impairment should be excluded from a Cerebrolysin® medical care. Animal experimental information didn’t show any proof to teratogenic effects. there’s no clinical experience with Cerebrolysin® in women.
Therefore, unless the potential advantages outweigh any potential risk.
Cerebrolysin® mustn’t be administered throughout preguancy and also the lactation period.


The concomitant administration of Cerebrolysin® with antidepressive medicine or MAO inhibitors will result in cumulative effects. In these cases a dosage reduction of the antidepressive drug is advisable .

Dasage and administration

Cerebrolysin® is available in various weights like 1ml, 5ml and 10ml ampoules and vials of 30ml and 50ml. Up to 5ml per intramuscular administration, for administration over 5ml an intravenous injection or infusion is suggested.

Once daily application of Cerebrolysin® for a minimum of ten to twenty days are suggested. This constitutes a course of medical care. In gentle cases 1-5ml, in severe cases 10-30ml should be applied. The length of the medical care and also the individual doses on the age of the patient further as on the illness. typically a treatment period of 3 to four weeks is usually recommended.

0 reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.